Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users
New brand boosts protein, iron, calcium content
Up against new Daily Harvest, Herbalife products
By Jessica DiNapoli
NEW YORK, May 21(Reuters) -Nestle NESN.S will market a new, $5 line of frozen pizzas and protein-enriched pastas in the United States which it says it designed specifically for people taking drugs such as Wegovy or Ozempic for weight loss.
The world's biggest food company, which sells DiGiorno pizza and Stouffer's meals to major grocers, said it developed the new products with more protein, iron and calcium for people taking the wildly popular appetite-suppressing drugs, called GLP-1 agonists.
Tom Moe, president of Nestle USA's meal division, said it will pitch the meals in a new brand, Vital Pursuit, as "food solutions" for people who want to complement their use of the drugs with "the right nutrition - high protein, good fiber, the right minerals," like potassium and vitamin C.
The products, set to hit supermarket shelves in October, are priced at $4.99 and under, a little more expensive than a DiGiorno four cheese personal pan pizza, which is sold at Target for $4.79.
Nestle, whose biggest brands include KitKat chocolate bars and Nescafe coffee, started working on companion products to the GLP-1 drugs last year.
"We moved real fast on this," Moe said.
Nestle CEO Mark Schneider said in October the company was “carefully” monitoring whether spreading use of the drugs might dent demand for its food products. He also said at the time that Nestle was working on “companion products” that might serve to limit the "loss of lean muscle mass” in people on the drugs.
Some investors have been worried that food companies will lose sales due to the hunger-suppressing drugs. But executives at companies like Nestle and Conagra CAG.N see the medications presenting a new opportunity to pitch products such as beef jerky, popcorn and frozen meals. Mondelez MDLZ.O executives have said their snack bars fit perfectly into the diet of a GLP-1 patient.
Roughly one in eight U.S. adults have taken the GLP-1 drugs, but Goldman Sachs estimates that 10 million to 70 million U.S. consumers could be taking them in the next four years.
Moe said Nestle spoke with people on the drugs to develop the meals and will be offering them samples soon. The Swiss-based company first introduced the brand to Walmart WMT.N, and then other big retailers such as Kroger KR.N and Target TGT.N, he said.
RACE ON TO FILL PROTEIN GAP
People on GLP-1 medications are at risk of losing lean muscle mass as they shed pounds and often don’t feel like eating very much, said Ethan Lazarus, an obesity doctor in Colorado. Some who take the drugs develop aversions to protein and fat, said Lazarus, who is a speaker for GLP-1-drugmakers Eli Lilly LLY.N and Novo Nordisk NOVOb.CO.
“There’s definitely a need to make sure people get adequate protein,” said Lazarus, who once served on the advisory board for Nestle Health Sciences, which makes Optifast, a weight loss product.
“If food companies are going to try to pivot to make simple-flavored foods that are rich in protein and easy on the stomach, they might be popular ... I’m not sure how it’s different from (previous generations of packaged) diet food.”
Nestle already makes weight loss shakes and supplements that cater to people on the drugs, who can experience side effects like nausea and constipation.
Nutrition company Herbalife HLF.N earlier this year began selling some of its most popular shake mixes and fiber supplements in bundles targeting people on the drugs.
Herbalife is looking at expanding the bundles to other markets, including South America and in particular Brazil, where GLP-1 drugs are growing in popularity, said Luigi Gratton, chairman of the company's nutrition advisory board.
Meal kit provider Daily Harvest is also offering a GLP-1 companion food collection, a box of meals that includes a broccoli and white bean soup and bean and cabbage bowl for $118.46.
Sales have been "relatively slow," said Daily Harvest CEO Ricky Silver. The company isn't aggressively pushing into selling its kits to people on the medications, he said.
"We definitely see it as an opportunity (but) not something we need to drastically pivot our focus toward," Silver said. "Our food is already foundationally good for people taking these drugs."
Nestle's Vital Pursuit's portions will range from approximately eight to 10 ounces (227 to 284 grams), Moe said.
In the 1980s, Nestle introduced diet brand Lean Cuisine, with meals focused on calorie control, while Vital Pursuit offers more fiber, protein and other "macronutrients," Moe said.
Reporting by Jessica DiNapoli in New York; Editing by Sonali Paul
Ativos relacionados
Últimas notícias
Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.
Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.
Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.
